Table 1.
Baseline demographics and clinical outcomes.
| Demographic variable* | |
|---|---|
| Average age, mean (SD) | 65.82 (10.88) |
| Gender, n(%) | |
| Male | 14 (63.6) |
| Female | 8 (36.3) |
| Diabetes mellitus, n(%) | 9 (40.9) |
| Hypertension, n(%) | 11 (50) |
| Portion receiving PSTA, n(%) | 6 (27.3) |
| Average follow up duration, weeks, mean(SD) | 54.45 (7.65) |
| Average number of IVI injections, n, mean(SD) | 3.54 (1.74) |
| Average number of IVI in first 3 months, n, mean(SD) | 2 (0.87) |
| Average initial BCVA, mean(SD) | 45.86 (19.46) |
| Average final BCVA, mean(SD) | 69.77 (29.58) |
| Average BCVA improvement, mean(SD) | 23.91 (17.36), P < .0001 |
| Average initial CRT, μm, mean(SD) | 562.50 (164.02) |
| Average final CRT, μm, mean(SD) | 280.95 (53.61) |
| Average CRT improvement, μm, mean(SD) | 245.55 (153.31), P < .0001 |
*
0 patient in group 1.
BCVA = best-corrected distance visual acuity, display by ETDRS letter score; CRT = central retinal thickness; IVI = intravitreal injection; HTN = hypertension, PSTA = posterior sub-tenon’s triamcinolone acetonide; SD = standard deviation.